Skip to content

EyePoint, Inc. EYPT Total Equity

Total Equity at other companies

Merck & Co. logo
Merck & Co.MRK
$45.88B-5.1%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$31.42B+6.9%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
$581.57M+119%
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
$112.1M+3.0%
HRO
HarrowHROW
$28.71M-49.1%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-$236M-264%

Other financials

Income statement

See full
Revenue$696.0K-97.2%
Gross profit$9.8M-30.1%
Operating income-$87.2M-78.6%
Net income-$84.8M-87.7%
EPS (diluted)-$0.99-52.3%

Balance sheet

See full
Cash & equivalents$77.7M-8.7%
Total debt$22.3M-7.3%
Total assets$288.2M-20.5%

Cash flow

See full
Operating cash flow-$80.5M-51.6%
CapEx$997.0K+261%
Free cash flow-$81.5M-52.7%

Valuation

See full
Market cap$1.21B+189%
Enterprise value$1.15B+228%
P/S158.5×+151×

Profitability

See full
Operating margin-3,700.9%-4,042pp
Net margin-3,566.6%-3,874pp
FCF margin-3,565.9%-3,884pp

Returns & leverage

See full
Return on equity-102.7%+1,157pp
Debt / equity0.1×0.0×
Current ratio6.7×-1.2×

Where this comes from

Reported directly by EyePoint, Inc. in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The official record: EyePoint, Inc. ’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about EyePoint, Inc. 's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is EyePoint, Inc. 's total equity?
EyePoint, Inc. (EYPT) reported total equity of $230.47M in Q1 2026.
How has EyePoint, Inc. 's total equity changed year-over-year?
EyePoint, Inc. 's total equity decreased by 22.8% year-over-year, from $298.4M to $230.47M.
What is the long-term trend for EyePoint, Inc. 's total equity?
Over 5 years (2020 to 2025), EyePoint, Inc. 's total equity has grown at a 75.2% compound annual growth rate (CAGR), from $18.54M to $306.11M.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.